In NYU Langone’s Division of Neuromuscular Medicine, our research interests include peripheral neuropathy, myasthenia gravis, chemotherapy-associated neuromuscular diseases, and COVID-19–related neuromuscular conditions. Division investigators are examining the association between immune checkpoint inhibitor chemotherapy and the development of associated peripheral neuropathies, neuromuscular junction disorders, and inflammatory myopathies.

Our investigators are also examining neuromuscular complaints associated with the post-acute sequelae of COVID-19 (PASC) and how symptoms change or improve over time. Similar to our efforts in examining the association between neuropathic symptoms and exposure to the 9/11 World Trade Center disaster, we have an interest in exploring if there is a relationship between new-onset neuropathy and COVID-19 infection.

Neuromuscular Medicine Clinical Trials

See below for a list of active clinical trials.

Effects of N-Acetyl-L-Leucine on GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease): A Multinational Multicenter Open-Label Rater-Blinded Phase II Study
Principal investigator: Claire Miller, MD, PhD

A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)
Principal investigator: Jeffrey S. Weber, MD, PhD

Registry of COVID-19 Survivors: Assessment of ICU and Non-ICU Survivors: A Creation of a COVID Survivorship Database
Principal investigator: Rany Condos, MD